Agoracom Blog Home

Posts Tagged ‘smallcap stocks’

Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:11 PM on Friday, October 9th, 2020
Innocan-Blog
  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Herzliya, Israel and Calgary, Alberta–(October 9, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol (“CBD”) into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan’s licensed CBD loaded liposome platform technology (“LPT”) for injectable CBD.

The study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Berenholz, was conducted in The Hebrew University of Jerusalem laboratories on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT.

These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.

These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of The Hebrew University of Jerusalem in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which was the inventor of over 55 patent families, two of which underlie Doxil® – an FDA approved drug for breast cancer treatment. This unique technology platform may be implemented for several indications such as epilepsy, pain relief, and different inflammation and central nervous system disorders. A patent was filed on this technology on October 7, 2019.

Professor Chezy Berenholz stated, ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”

Iris Bincovich, Innocan’s CEO, added, “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Innocan Pharma $INNO.ca to Provide a Corporate Update via Livestream Video $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:10 PM on Thursday, October 8th, 2020
Innocan-Blog
  • Will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.
  • update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

Herzliya, Israel and Calgary, Alberta–(October 8, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing Cannabidoil (“CBD”). Innocan Israel, a wholly owned subsidiary of the Company, and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 9:37 AM on Monday, October 5th, 2020

InnoCan Pharma (INNO:CSE) Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids. InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. Learn more.

Innocan-Blog

How Richard Carleton Is Leading The Cannabis Revolution At The CSE

Cannabis has emerged as a viable commodity for international trade, and the Canadian Stock Exchange is leading the charge.

  • A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations
  • InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes
  • This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

The growing cannabis market

As the cannabis industry continues to advance, more and more companies are moving to get their stocks listed on Canada Securities Exchange. Cannabis is no longer just a plant. The debate on its legality, decriminalization, health benefits, among others, are now the main focus of attention. Cannabis has emerged as a viable commodity for international trade, and raw material for consumption, with several companies listed on the stock market and shareholders who speculate on its rise or fall according to news of its legalization in more corners.

A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations. InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes. This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

Although the debate will always be present, more and more countries have chosen to decriminalize and even promote the use of cannabis, especially for medicinal purposes. The likes of Germany, Argentina, Italy, Canada, etc already allow the use of CBD derivatives to treat health problems, always under medical prescription, but often even facilitating their access to patients.

Cannabis for recreational activities is now an emerging discourse, and borders that seemed immovable a while ago have been crossed. Canada passed a regulation in 2018 that made it one of the few countries that fully allowed recreational consumption and the first of the G-8.

It thus joined Uruguay, a country that has always had a fairly permissive position. And the Netherlands, which despite the fame of its cannabis sale in coffee shops, has not changed its regulation in recent years (The Netherlands does not allow cultivation for self-consumption). As well as Mexico, who in a wide debate in recent years, have legalized marijuana for medical use. In the United States, almost 30 of its states have opened the door to medicinal consumption, and about 10 of them, including California, to recreational use.

The growth of the marijuana-related market has exploded in recent years and according to GlobeNewswire, “The global legal marijuana market size is expected to reach USD 73.6 billion by 2027.” This includes medicinal, recreational, and derivatives.

Furthermore, “It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. Based on type, the medical segment held the leading revenue share of 71% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, an increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.”

In this context, in recent years numerous companies, especially in the pharmaceutical industry, have begun to fully immerse themselves in this buoyant market with the expectation that over time it will become increasingly legal in more countries. Most of these companies are Canadian, and they have emerged in the glow of the country’s decriminalization momentum.

Some are dedicated to distribution for recreational consumption, those that lean more to the medical side, and those that are specializing in derivatives. Several things unite them: they are all Canadian for their reference in legalization, they are all growing, and a lot of them have successfully been listed on the stock market.

Canadian Securities Exchange (CSE)

Without a doubt, the Canadian Securities Exchange (CSE) has played a vital role in strengthening the marijuana-related market in Canada. Led by a visionary CEO, Richard Carleton, it has emerged as one of the pillars of cannabis investment in the country. Exchange operators have critically guided affairs, bringing about the availability of a variety of investment options for cannabis investors.

The CSE is Canada’s fastest-growing stock exchange. With more than 600 listings and a cumulative market capitalization of approximately C$23 billion, the Exchange continues to attract entrepreneurial companies that are looking for the most efficient path to the North American capital markets. With the help of the Canada Securities Exchange, Canadian companies can choose to test the waters outside Canada, particularly in the United States, as long as they can allay the fears of shareholders. Presently, cannabis is illegal on a federal level in the USA, however, it is legal for medical and recreational purposes in a good number of states.

The Canadian Securities Exchange (CSE) is the go-to platform for cannabis companies who are still developing. It offers much-needed exposure for the growth of these emerging companies, while also giving established organizations, such as multi-state operators in the US, a chance to gain a competitive advantage in the global market.

According to Richard Carleton, “It is always gratifying to see companies capitalizing on opportunities in the public market to pursue their vision for growth. The CSE has a mandate to facilitate entrepreneurial activity such as this.”

Looking at the medical aspect, he further believes that large and small companies have complementary roles in the pharmaceutical industry. Start-up companies play an important role in conducting early research and development in identifying new drug therapies. History shows that a lot of value creation happens in this space before the drugs are taken through clinical trials and ultimately brought to the market by the pharma giants and are prescribed to patients worldwide. In addition, regardless of their size, pharma companies need to have exceptional technical and logistical talent to develop a drug and move it through regulated trials.

Presently, there is a tremendous amount of effort in the pursuit of therapies and vaccines for COVID-19. This recent activity is a good reminder of how powerful the public markets are at organizing capital to solve real-world issues. You can be sure that whatever health challenge society is presented with next, the market will be here to find solutions.

https://seekingalpha.com/instablog/52407514-dennz54/5504073-how-richard-carleton-is-leading-cannabis-revolution-cse

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 5:36 PM on Friday, September 25th, 2020
Innocan-Blog

(INNO:CSE)

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements – Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements – United Kingdom and Ireland

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commenced In H2 2020 during September

SEEING IS BELIEVING

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

VIDEO: Innocan $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) #CBD Premium Facial Serum on Skin Hydration $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 12:15 PM on Wednesday, September 16th, 2020
Innocan-Blog

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) on skin hydration.

  • Study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”.
  • The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin.
  • The results demonstrated that there were significant hydration increases for each period.
  • The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

Read Full Release

CEO SPOTLIGHT: Iris Bincovich, CEO of Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:52 PM on Tuesday, September 15th, 2020
Innocan-Blog

Hub On AGORACOM / Corporate Profile

My Search for the Healthiest Baby Formula – SPONSOR: Else Nutrition $BABY.ca $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 6:12 PM on Thursday, May 7th, 2020

SPONSOR: Else Nutrition Holdings Inc. (TSX-V: BABY)The award winning, plant-based nutrition company for small cap investors. The company has a $10,000,000 cash balance for US product launch In Q2 2020 with International agreements in Q3. Learn More

http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

My Search for the Healthiest Baby Formula

by Robin Barrie Kaiden, MS, RD, CDN

Robin Barrie Kaiden, MS, RD, CDN is renowned for helping people of all ages embrace a healthier lifestyle through nutrition and fitness counseling.  As a Licensed Registered Dietitian and Personal Trainer, her smart and sensible approach to pediatrics, weight loss, sports nutrition, allergies, cardiovascular health, pre/post natal, and other areas of clinical and lifestyle nutrition has resonated with hundreds of people across the United States. Robin received her B.S. and M.S. degrees in Nutrition and Exercise Science from Cornell and Columbia Universities.

A Personal Note from this Pediatric Registered Dietitian and Mom

When I began working as a Registered Dietitian in Pediatric Nutrition over 15 years ago, we, of course, were taught, and shared with patients, that breast milk was the best, healthiest option for feeding babies.  When that wasn’t possible, sufficient, or babies were being weaned, I knew that there were a variety of infant and toddler formulas available. We could recommend:

  1. Pre-term infant formula:  higher calories and minerals for infants born early
  2. Standard term infant formula:  intact milk protein
  3. Gentle/sensitive formulas: whey protein in milk partially broken down
  4. Soy-based formulas:  for those with milk intolerance, noting that over 50% of infants who don’t tolerate dairy, also do not tolerate soy protein
  5. Hydrolyzed formulas:  proteins are mostly, but not completely broken down
  6. Elemental formulas:  proteins completely broken down for severe milk allergies

At this point in my career, I did not study the ingredients of each, but rather selected the best option available to best aid in tolerance, intake and growth for the child.  There always seemed to be one that worked well…..at least well enough. The biggest problem with the hydrolyzed and elemental formulas was that they smelled and tasted terrible, and babies often refused to drink them.

Over 8 years ago, when I was pregnant with my first baby, I began to examine the healthiest baby formula options more in depth.   I discovered that not much had changed in this industry, except that there were a couple of organic options. After discussing with a colleague, I decided on a formula.  When my son was less than a week old, this product was recalled due to high arsenic levels. Plus, it seemed to upset his stomach. When my baby nurse suggested a non-organic, but “gentle” formula, I (reluctantly) agreed.  I disliked that it had corn syrup (processed inflammatory sugar) as one of the main ingredients, but I was a new mom, overwhelmed, and figured she had so much experience and knew what she was talking about. Plus, my pediatrician agreed as well.  A few weeks later, I just went back to the only other organic option on the market, and my son seemed to tolerate it well enough. It was the best I could find at that time. 

When it came time to find the healthiest baby formula for my second child, almost 2.5 years later, I become aware that there were some European products that had better ingredients.  However, it was pretty difficult and expensive to get these in the U.S. back then. I took comfort in the fact that my baby would be able to get great nutrition in the form of real food within about 4-5 months, and wean off formula totally at 1 year.  But all I could think was that I would love to create a new healthy baby formula myself. Why hadn’t someone come up with a better alternative yet? Aren’t the infant and toddler stages the most important as they are developing and growing so rapidly? Why wouldn’t everyone want offer the best possible nutrients to this group, if/when/after breast milk was not an option.

My children are now in elementary school and the infant/toddler formula industry is still, in my opinion extremely limited.  I was thrilled to hear about Else Nutrition, and flattered to consult on their timely products. Formulation of plant-based products is way overdue.   In the wake of a huge movement towards plant-based and plant-forward diets, due to increased research and interest, Else is a wonderful product to support infant and toddler Nutrition.  Read on to learn about all of its positive attributes.

Benefits of Else Plant-Based Formula Alternative

Choose Else Nutrition because it is:

  1. Organic:  This means that the USDA (United States Department of Agriculture) has determined that the ingredients in this healthy baby formula are free of genetically modified organisms (GMOs), fungicides, herbicides, and pesticides.   Organic practices result in enhanced soil and water quality and, in general, more overall sustainable farming (1).  Translation:  Organic foods are beneficial for our environment.  Research has shown that organic produce is more nutritious:  It has higher levels of antioxidants and lower levels of toxic metals (such as Cadmium).   Increased exposure to pesticides has been shown to increase risk for ADHD, Parkinson’s disease, diabetes, and some cancers (2).  The effects of chemicals used in conventional farming may be more detrimental to the small developing brains and bodies of babies/children than to those of adults. 
  2.  Glyphosate-free:  Yes, the USDA Organic Label is important, however, it may not be enough today.  It ensures that crops are GMO-free, but this doesn’t mean a product is 100% free of pesticides.   Glyphosate is an herbicide (pesticide) that is carcinogenic (can cause cancer). Final organic food products are often NOT tested.  The USDA does not check for glyphosate residue. The buckwheat and almond sources in Else formulas are glyphosate-free.
  3. Made from clean ingredients:  Else formulas are simple and pure.  Almonds, buckwheat, and tapioca make up about 92% of the product.  The ingredient list is short and easy to understand. There are no added unhealthy oils, inflammatory sugar/corn syrups, artificial sweeteners, or gums/stabilizers/fillers than can upset small bellies.   For moms looking to supplement breast milk or wean their children after 1 year of age, it may seem that there are many dairy-free milk substitutes and products on the market today; however, none are quite right for little developing brains and bodies.  They are not nearly as nutritionally dense as breast milk (or full-fat dairy milk). They may be low-fat, low in protein, and other nutrients, and often contain added sugars and fillers as mentioned above. They are simply NOT appropriate, and in fact, unhealthy as a foundation for a toddler’s diet.  This is especially true for vegans and/or those who truly cannot tolerate dairy protein.
  4. Pleasantly mild in flavor:  When babies are weaned off breast milk and/or need a supplement or substitute for human or cow’s milk, they are more likely to accept a drink/formula that tastes great (they are indeed little humans).  Other formulas may not be as mild.  In fact, the hydrolyzed/elemental formulas have a reputation of smelling bad and tasting worse.  Such formulas may be indicated for little ones with dairy allergies and intolerances, and digested well; however, if the child will not drink due to the smell/taste, this can be an issue.  
  5. Vegan/Plant-based:  In case you haven’t noticed, there has been a huge buzz surrounding “plant-based” and “plant-forward” nutrition.  This is not new news to us health professionals. We have always known that a variety of fruits, vegetables, whole grains, legumes, fiber, and healthy fats were integral for good health.  The research is finally catching up. We now know that our microbiome (the collection of microorganisms-bacteria, fungi, viruses-that live in/on the human body) can benefit our health, especially immunity, aging, digestion, metabolism, mood and mental health.   We can best benefit our microbiome by consuming a diet rich in a variety of plant-based foods. Why not start our little ones on such a diet with a plant-based formula?! Research shows that children on a predominantly plant-based diet have increased microbial biodiversity and richness (3).  
  6. Dairy-Free and Soy-free:  Infants and toddlers with food allergies, intolerances, and/or sensitivities simply cannot tolerate many formulas on the market today.  The incidence of food allergies is on the rise in children and adults. According to the Mayo Clinic: “Food allergy is an immune system reaction that occurs soon after eating a certain food. Even a tiny amount of the allergy-causing food can trigger signs and symptoms such as digestive problems, hives or swollen airways. In some people, a food allergy can cause severe symptoms or even a life-threatening reaction known as anaphylaxis.”(4)  Cow’s milk is the most allergenic food for in children in the U.S. (followed by peanuts, eggs and soy).  Most of the formulas on the market are based on cow’s milk.  

Else’s products can be tolerated by children with dairy and soy allergies and sensitivities.  Anaphylaxis due to almond or buckwheat allergy is very rare (<1% and 1% of anaphylaxis cases in children respectively) with numbers well below egg, wheat, fish, goat/sheep’s milk, lentils, cashew, and peanut.

Also, just as an update and reminder about almonds:  recent research demonstrates that delaying introduction of potential allergenic foods (wheat, dairy, eggs, fish and nuts) may actually increase the risk of food allergies and/ or eczema.  The American Academy of Asthma, Allergy and Immunology (AAAAI) now recommends they be introduced without delay, and not wait up to 1-3 years of age, as advised in the past (5).

  1. Nutrient composition matches breast milk:  We all know that breast milk is the gold standard for feeding infants.  However, if and when it is not possible, and/or a child requires supplementation or is being weaned, Else Nutrition provides a formula with nutrients that match that of breast milk.  The macronutrients (carbohydrates, fat, and protein) and micronutrients (vitamins and minerals) are the same in Else formula-even though Else is a vegan product. Moms and caregivers can be confident that their babies are being nourished while they slowly learn how to eat solids.   
  2. Created and supported by the best team:  These formulas were created by leaders in the infant and toddler nutrition industry.   Their formulation and ingredients have been tested, approved, and supported by pediatricians, gastroenterologists, registered dietitians, and MOMS and DADS!  

References:

  1. https://www.ams.usda.gov/sites/default/files/media/Organic%20Practices%20Factsheet.pdf
  2. https://www.ncbi.nlm.nih.gov/pubmed/29073935
  3. https://www.ncbi.nlm.nih.gov/pubmed/20679230
  4. https://www.mayoclinic.org/diseases-conditions/food-allergy/symptoms-causes/syc-20355095
  5. https://www.jaci-inpractice.org/article/S2213-2198(12)00014-1/fulltext

Source: https://elsenutrition.com/blogs/news/my-search-for-the-healthiest-baby-formula

Toddler Meal Ideas for Picky Eaters – SPONSOR: Else Nutrition $BABY.ca $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 5:07 PM on Wednesday, April 29th, 2020

SPONSOR: Else Nutrition Holdings Inc. (TSX-V: BABY)The award winning, plant-based nutrition company for small cap investors. The company has a $10,000,000 cash balance for US product launch In Q2 2020 with International agreements in Q3. Learn More

Toddler Meal Ideas for Picky Eaters

By Nicole Silber, RD, CSP, CLC

Children undergo more changes to their growth, development and eating patterns in the years between birth and preschool than any other time in their lives. When babies turn into toddlers, their relatively consistent, predictable eating becomes very inconsistent, paving the way for what many parents would describe as picky eating.

Many parents are concerned with how their toddlers eat (and don’t eat for that matter). What we do know from the Feeding Infants and Toddlers Study (FITS) is that many toddlers and preschoolers eat too much sodium and saturated fat, and not enough key nutrients like potassium, Vitamin D and fiber. But, some of the concerns that I hear from parents regarding their toddlers’ eating stem from a gap in knowing just how much healthy toddlers actually need, and what are normal versus problematic eating behaviors. These concerns usually lead to mealtime tensions, which can perpetuate the picky eating cycle.

Understanding the Needs for Toddler Meals

Understanding what is normal can be very helpful for parents.  Expect toddler meals to be consistently inconsistent – meaning they may skip occasional meals (yes, that means eat a few bites, or nothing), show fluctuating appetites daily based on changing growth needs (meaning when they’re going through a growth spurt they eat much more), and refuse foods one day that they gobbled up the day before. Their willingness to eat at meals may be affected by too much snacking (or grazing), fear of new foods that suddenly develop, or any minor discomfort from teething, a cold or even constipation can impact their willingness to put certain foods, textures and flavors into their mouths. And as a reminder, toddlers are much smaller than adults, so they do not need adult-like portions. For example, healthy toddlers need just 1 cup of veggies each day, so if that’s broken up into 2 meals and a snack that can be just 1/3 of a cup per sitting.  One day they may eat double that, and the next eat none, so look at the average.

Managing expectations can help relieve some parental stress and make way for more positive mealtime environments.  Pushing too hard, trying to convince, sneaking foods, accommodating requests (going to the kitchen and making 3 different dinners), offering bribes to finish the broccoli (yes, we’ve all been there) are all tempting, but can create power struggles that actually intensify the feeding refusals. But, there are some productive things that parents can do to encourage more variety with picky eaters, and the American Academy of Pediatrics (AAP) offers some great tips, like including children in cooking, encouraging family meals, and offering foods repeatedly and in flavorful ways.

Supplementing Toddler Meal Ideas With Something Else

While it’s developmentally normal for toddlers to go through some picky eating phases, some children, and parents alike, struggle to eat balanced, varied meals. And, for children who have any major diet restrictions because of allergies, medical or other lifestyle reasons, they are at higher risk for nutritional deficiencies during times of picky eating. That is when a fortified toddler nutrition drink, like Else, can be a great supplement to their diets. Else complete plant-based toddler meals can help in 2 ways: A more direct benefit is that Else provides these children with an extra boost of calories, fat (particularly unsaturated fat), protein, fiber, omega 3s and many key vitamins and minerals, like iron, potassium, vitamin D needed to support this time of rapid growth. And, Else can provide parents with the reassurance that their little ones are getting the nutrients they need. This reassurance can minimize the stress and pressure placed by parents and felt by kids at mealtimes, which can ultimately encourage more relaxed, varied eating.

Source: https://elsenutrition.com/blogs/news/easy-toddler-meal-ideas-for-picky-eaters

Else Nutrition $BABY.ca Announces Filing of Preliminary Base Shelf Prospectus $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 12:25 PM on Tuesday, April 28th, 2020
  • Filed its preliminary base shelf prospectus
  • Filing of the Shelf Prospectus, when made final, will allow the Company to qualify the distribution by way of prospectus in British Columbia, Alberta and Ontario of up to C$20,000,000 of common shares, warrants to purchase common shares, units, or any combination thereof, during the 25-month period that the Shelf Prospectus is effective

Not for Distribution in the U.S. or to U.S. Newswire Services

VANCOUVER, BC / April 28, 2020 / Else Nutrition Holdings Inc. (the “Company” or “Else Nutrition” or “Else“) (TSXV:BABY) (OTCQB:BABYF) is pleased to announce that today it has filed its preliminary base shelf prospectus (the “Shelf Prospectus“) with the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission. A copy of the Shelf Prospectus can be found on the Company’s SEDAR profile at www.sedar.com.

The filing of the Shelf Prospectus, when made final, will allow the Company to qualify the distribution by way of prospectus in British Columbia, Alberta and Ontario of up to C$20,000,000 of common shares, warrants to purchase common shares, units, or any combination thereof, during the 25-month period that the Shelf Prospectus is effective. Should the Company decide to offer securities during this period, the specific terms, including the use of proceeds from any offering, will be set forth in a related prospectus supplement to the Shelf Prospectus, which will be filed with the applicable securities commissions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the qualification under the securities laws of any such jurisdiction.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition GH Ltd. (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly-traded company, listed on the TSX Venture Exchange under the trading symbol “BABY” and is quoted on the US OTC Markets QB board under the trading symbol “BABYF”. The Company’s Executive and Advisory Board includes leaders hailing from Abbott Nutrition, Mead Johnson, Boston Children’s Hospital, ESPHGAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition), Plum Organics, Tel Aviv University’s Sackler Faculty of Medicine, and Gastroenterology & Nutrition Institute of RAMBAM Medical Center.

For further information, please contact:

Ms. Hamutal Yitzhak, CEO of Else Nutrition
Email: [email protected]

Mr. Sokhie Puar, Director of Else Nutrition
Telephone: 604-603-7787
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities described herein have not been registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act and any applicable state securities laws.

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Shelf Prospectus. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the receipt of all necessary regulatory approvals, use of proceeds from the financing, capital expenditures and other costs, and financing and additional capital requirements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. The Company will not update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.

VIDEO: Else Nutrition $BABY.ca Has $10M In Cash And A Billion Dollar Shareholder To Launch Plant Based Toddler Foods Around The World $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 6:04 PM on Monday, April 27th, 2020

When the subsidiary of a Billion Dollar, Nutrition Focused company buys 11.5% of your stock, agrees to a voluntary 12-month lock up and holds anti-dilution rights to maintain it’s ownership percentage by buying a proportionate number of shares in any future financing, it is safe to assume you have a strategic investor who believes in the future of your company.    When that same strategic investor wants to then help your company expand into large international markets, it is safe to assume your plant based food capabilities are amongst the most respected in the world.   This is just a glimpse into the strength of Else Nutrition (BABY:TSXV) (BABYF:OTCQB), an Israeli based, award winning plant based food nutrition company that is giving small cap investors an opportunity to participate in the global paradigm shift towards plant-based, clean label foods.   BUT THERE IS MORE

  • Else has a $10,000,000 war chest for a US product launch in Q2 and to start signing international agreements in Q3. 
  • These global plans are supported by patents in 22 countries, with another 44 countries pending.  
  • Else developed the world’s first 100% plant based, non-dairy, non-soy baby formula

Given all of these achievements, it should come as no surprise that Else Nutrition is made up of Executives & Advisors from globally renowned companies and institutions.   If you believe in the future of plant-based, clean label foods or want to discover its possibilities, then watch our first ever interview with Hamutal Yitzhak, the CEO and Co-Founder of Else Nutrition who will tell you about both the Company’s origins and future path.